Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - tolterodine tartrate - oral tablet - 2mg

Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

torrent pharma (uk) ltd - tolterodine tartrate - oral tablet - 2mg

Bandaríkin - enska - NLM (National Library of Medicine)

cardinal health - tolterodine tartrate (unii: 5t619tqr3r) (tolterodine - unii:whe7a56u7k) - tolterodine tartrate 2 mg - detrol la capsules is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency [see clinical studies (14) ]. detrol la is contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. detrol la is also contraindicated in patients with known hypersensitivity to the drug or its ingredients, or to fesoterodine fumarate extended-release tablets which, like detrol la, are metabolized to 5-hydroxymethyl tolterodine [see warnings and precautions (5.2) (5.3), (5.4) ]. pregnancy category c. at approximately 9–12 times the clinical exposure to the pharmacologically active components of detrol® la, no anomalies or malformations were observed in mice (based on the auc of tolterodine and its 5-hmt metabolite at a dose of 20 mg/kg/day). at 14–18 times the exposure (doses of 30 to 40 mg/kg/day) in mice, tolterodine has been shown to be embryolethal and reduce fetal weight, and increase the incidence of fetal abno

Bandaríkin - enska - NLM (National Library of Medicine)

physicians total care, inc. - tolterodine tartrate (unii: 5t619tqr3r) (tolterodine - unii:whe7a56u7k) - tolterodine tartrate 2 mg - detrol la capsules is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency [see clinical studies (14) ]. - urinary retention - gastric retention - uncontrolled narrow-angle glaucoma [see warnings and precautions (5.1), (5.3) ] . pregnancy category c. at approximately 9–12 times the clinical exposure to the pharmacologically active components of detrol® la, no anomalies or malformations were observed in mice (based on the auc of tolterodine and its 5-hmt metabolite at a dose of 20 mg/kg/day). at 14–18 times the exposure (doses of 30 to 40 mg/kg/day) in mice, tolterodine has been shown to be embryolethal and reduce fetal weight, and increase the incidence of fetal abnormalities (cleft palate, digital abnormalities, intra-abdominal hemorrhage, and various skeletal abnormalities, primarily reduced ossification). pregnant rabbits treated subcutaneously at about 0.3 – 2.5 times the clinical exposure (dose of 0.8 mg/kg/day) did not show any

Írland - enska - HPRA (Health Products Regulatory Authority)

accord healthcare limited - tolterodine tartrate - prolonged-release capsule - 4 milligram(s) - drugs for urinary frequency and incontinence; tolterodine

Írland - enska - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - tolterodine tartrate - prolonged-release capsule, hard - 4 milligram(s) - drugs for urinary frequency and incontinence; tolterodine

Bandaríkin - enska - NLM (National Library of Medicine)

a-s medication solutions - tolterodine tartrate (unii: 5t619tqr3r) (tolterodine - unii:whe7a56u7k) - tolterodine tartrate extended-release capsules are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency [see clinical studies (14) ]. tolterodine tartrate extended-release capsules are contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. tolterodine tartrate extended-release capsules are also contraindicated in patients with known hypersensitivity to the drug or its ingredients, or to fesoterodine fumarate extended-release tablets which, like tolterodine tartrate extended-release capsules, are metabolized to 5-hydroxymethyl tolterodine [see warnings and precautions (5.2), (5.3), (5.4) ]. risk summary there are no available data with tolterodine tartrate extended-release capsules use in pregnant women to inform drug-associated risks. in animal reproduction studies, oral administration of tolterodine and its 5-hmt metabolite to pregnant mice during organogenesis did not produce adverse develo

Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - tolterodine tartrate - modified-release capsule - 4mg

Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - tolterodine tartrate - modified-release capsule - 4mg

Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - tolterodine tartrate - modified-release capsule - 4mg